Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Join the brightest minds in regulatory at the annual Regulatory Convergence. See the global regulatory community in action. Intensive workshops. Topical sessions. Meet ups with regulators. This is where it all comes together.
Learn how recent changes to the regulation of healthcare products in the EU will impact you as a regulatory professional.
In light of the COVID-19 pandemic, the RAC Board has elected to offer online testing with live online proctoring this summer.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.
Posted 02 August 2012 | By Louise Zornoza,
The European Medicines Agency (EMA) is phasing out so-called "follow-up measures" for human drugs requiring post-marketing studies this month, instead replacing them with three categories of post-marketing commitments:
The old "follow-up measures" established studies and other activities that the European Medicines Agency and the Committee for Human Medicinal Products had asked the marketing authorization holder to perform.
This new system of classification is being implemented in stages. The first phase tackled initial marketing-authorization-application opinions as of June 2011, followed by post-authorization procedures starting in November 2011. Companies affected by the new classification changes will receive an outcome fax for each applicable product that will include information about the new classification of follow-up measures, together with any actions that they need to take.
Read more:
EMA - European Medicines Agency phasing out follow-up measures
Read more Breaking News from RegLink
Tags: Follow-up Measures, Postmarketing Commitments, Phase IV, MAA, Latest News, marketing, MAH
Regulatory Focus newsletters
All the biggest regulatory news and happenings.